Showing results (101-110 of 130) with videos related to

Sort By:
Pageof 13
Transplantation|August 22, 2022
Outcomes of Sorafenib for Recurrent Hepatocellular Carcinoma After Liver Transplantation in the Era of Combined and Sequential TreatmentsFrancesco Tovoli, Dante Pio Pallotta, Vito Sansone, et al.
Journal of Cancer Research and Clinical Oncology|December 18, 2017
Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuationFranco Trevisani, Giovanni Brandi, Francesca Garuti, et al.
Journal of Hepatology|November 7, 2022
Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT studyMasatoshi Kudo, Richard S Finn, Shukui Qin, et al.
Expert Review of Gastroenterology & Hepatology|October 22, 2024
Delivering adjuvant and neoadjuvant treatments in the early stages of hepatocellular carcinomaBernardo Stefanini, Giulia F Manfredi, Antonio D'Alessio, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|August 21, 2024
Suboptimal outcomes of sorafenib as a second-line treatment after atezolizumab-bevacizumab for unresectable hepatocellular carcinomaFrancesco Tovoli, Dante Pio Pallotta, Caterina Vivaldi, et al.
European Journal of Cancer (Oxford, England : 1990)|October 7, 2017
Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationaleAndrea Casadei Gardini, Luca Faloppi, Serena De Matteis, et al.
Plos One|May 8, 2020
The role of PNI to predict survival in advanced hepatocellular carcinoma treated with SorafenibFrancesco Caputo, Vincenzo Dadduzio, Francesco Tovoli, et al.
JAMA Oncology|October 1, 2020
Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical TrialThomas Yau, Yoon-Koo Kang, Tae-You Kim, et al.
Targeted Oncology|October 28, 2020
Correction to: Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular CarcinomaGiulia Orsi, Francesco Tovoli, Vincenzo Dadduzio, et al.
Targeted Oncology|October 12, 2020
Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular CarcinomaGiulia Orsi, Francesco Tovoli, Vincenzo Dadduzio, et al.
Pageof 13